A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate

E. Weinblatt, Michael; M. Kremer, Joel; D. Bankhurst, Arthur; J. Bulpitt, Ken; Fleischmann, Roy; I. Fox, Robert; G. Jackson, Christopher; Lange, M.; Burge, Daniel

doi:10.1056/nejm199901283400401

Public

A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate

Published in New England Journal of Medicine • Jan 28, 1999

Authors:

Michael E. Weinblatt

Joel M. Kremer

Arthur D. Bankhurst

Abstract

BACKGROUND: Patients treated with methotrexate for rheumatoid arthritis often improve but continue to have active disease. This study was undertaken to determine whether the addition of etanercept, a soluble tumor necrosis factor receptor (p75):Fc fusion protein (TNFR:Fc), to methotrexate therapy wo...

Subject

Etanercept

Medicine

Methotrexate

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!